This News Story is more than 16 years old. Links and contact information may have changed.
Drug development expert to speak at 91探花 on September 23
| News
The Director of the Tufts Center for the Study of Drug Development (CSDD) will visit the 91探花 campus on September 23 to speak about the challenges of bringing new pharmaceuticals to market.
Entitled 鈥淧erspectives on the Drug Development Process: Current Challenges for the Research-Based Industry,鈥� the talk by Dr. Kenneth I. Kaitin runs from 9 to 10:30 a.m. in the New Residence, Room 142.
鈥淚n today鈥檚 competitive marketplace, research-based drug and biotech companies must not only maintain their focus on R&D efficiency and output,鈥� says Kaitin, 鈥渂ut they must also retain their ability to adjust to a rapidly changing and highly volatile R&D environment.鈥�
In his presentation, Kaitin will show how Tufts CSDD data will be used to document the current status of pharmaceutical innovation and explore the current economic, regulatory, and political challenges and opportunities facing drug developers today. He will also look at cost savings and efficiency gains that can be attained by adopting new strategies for R&D improvement and some of the challenges associated with the development of stratified and personalized medicines.
Kaitin is Director of the Tufts Center for the Study of Drug Development, an academic drug policy research group providing strategic information to help drug developers, regulators, and policy-makers improve the quality and efficiency of the drug development process. He is also Professor of Medicine at Tufts University School of Medicine, and he serves on the faculty of the European College of Pharmaceutical Medicine at the University of Basel.
He conducts research, lectures and writes on pharmaceutical development, regulation and public policy. He has written extensively on factors that contribute to the slow pace and high cost of pharmaceutical R&D and the impact of regulatory and legislative initiatives to speed new drug development and review.
Kaitin has provided public testimony before the U.S. Congress in hearings on pharmaceutical innovation and FDA reform, and he has worked closely with the U.S. Council on Competitiveness. He is on the board of directors of the New England Institute for Health Care Research and Innovation, and he served on the Center for Strategic and International Studies鈥� bioterrorism task force, 鈥淣ational Strategy for Anti-Biothreat Vaccines, Therapeutics and Diagnostics.鈥�
He is a former president of the Drug Information Association (1997-98) and editor-in-chief of the Drug Information Journal (2002-04). He currently serves on the editorial boards of several prestigious journals and on the boards of directors of two publicly held companies, Curis Pharmaceuticals, Inc. and Phase Forward, Inc., and the privately held company Bio-Tree Systems, Inc.
The 91探花 is hosting this talk in collaboration with the province of Prince Edward Island and the BioScience Networking Committee. To register, please contact Tammie at (902) 566-0564 or tmrose@upei.ca by Monday, September 22, 2008. Everyone is welcome.
Entitled 鈥淧erspectives on the Drug Development Process: Current Challenges for the Research-Based Industry,鈥� the talk by Dr. Kenneth I. Kaitin runs from 9 to 10:30 a.m. in the New Residence, Room 142.
鈥淚n today鈥檚 competitive marketplace, research-based drug and biotech companies must not only maintain their focus on R&D efficiency and output,鈥� says Kaitin, 鈥渂ut they must also retain their ability to adjust to a rapidly changing and highly volatile R&D environment.鈥�
In his presentation, Kaitin will show how Tufts CSDD data will be used to document the current status of pharmaceutical innovation and explore the current economic, regulatory, and political challenges and opportunities facing drug developers today. He will also look at cost savings and efficiency gains that can be attained by adopting new strategies for R&D improvement and some of the challenges associated with the development of stratified and personalized medicines.
Kaitin is Director of the Tufts Center for the Study of Drug Development, an academic drug policy research group providing strategic information to help drug developers, regulators, and policy-makers improve the quality and efficiency of the drug development process. He is also Professor of Medicine at Tufts University School of Medicine, and he serves on the faculty of the European College of Pharmaceutical Medicine at the University of Basel.
He conducts research, lectures and writes on pharmaceutical development, regulation and public policy. He has written extensively on factors that contribute to the slow pace and high cost of pharmaceutical R&D and the impact of regulatory and legislative initiatives to speed new drug development and review.
Kaitin has provided public testimony before the U.S. Congress in hearings on pharmaceutical innovation and FDA reform, and he has worked closely with the U.S. Council on Competitiveness. He is on the board of directors of the New England Institute for Health Care Research and Innovation, and he served on the Center for Strategic and International Studies鈥� bioterrorism task force, 鈥淣ational Strategy for Anti-Biothreat Vaccines, Therapeutics and Diagnostics.鈥�
He is a former president of the Drug Information Association (1997-98) and editor-in-chief of the Drug Information Journal (2002-04). He currently serves on the editorial boards of several prestigious journals and on the boards of directors of two publicly held companies, Curis Pharmaceuticals, Inc. and Phase Forward, Inc., and the privately held company Bio-Tree Systems, Inc.
The 91探花 is hosting this talk in collaboration with the province of Prince Edward Island and the BioScience Networking Committee. To register, please contact Tammie at (902) 566-0564 or tmrose@upei.ca by Monday, September 22, 2008. Everyone is welcome.
Contact
Anna MacDonald
Media Relations and Communications, Integrated Communications
